1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. MONOPAR THERAPEUTICS INC
Monopar Therapeutics Inc
XNAS: MNPR
Download real time
78.290.32(0.41%)
37.28% Fall from 52W High
128.3K
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Monopar Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Monopar Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Monopar Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Monopar Therapeutics Inc Jun-2026 Quarterly Net Profit is $-5 Million which is growth of -116.6% YoY.

Monopar Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
6.65.26.24.13.23.211.11.61.81.71.92.12.3
Operating Profit
-6.6-5.2-6.2-4.1-3.2-3.2-11.1-1.6-1.8-1.7-1.9-2.1-2.3
⌄
1.31.310.70.80.60.20.10.10.10.10.10.1
Profit Before Tax
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Tax
-------------
⌄
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Diluted NI Avail to Com Stockholders Ann.
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Basic EPS
-0.6-0.5-0.6-0.5-0.4-0.4-2.8-0.4-0.5-0.5-0.6-0.7-0.8
Diluted EPS After ExtraOrdinary
-0.6-0.5-0.6-0.5-0.4-0.4-2.8-0.4-0.5-0.5-0.6-0.7-0.8
Number Of Shares End
8.58.58.57.1774.93.53.53.22.92.82.7
Net Income Continuing Discontinued Operations
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Normalized Income
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Interest Income
1.31.310.70.80.60.20.10.10.10.10.10.1
Interest
-------------
Net Interest Income
1.31.310.70.80.60.20.10.10.10.10.10.1
EBIT
-6.6-5.2-6.2-4.1-3.2-3.2-11.1-1.6-1.8-1.7-1.9-2.1-2.3
EBITDA
-6.6-5.2-6.2-4.1-3.2-3.2-11.1-1.6-1.8-1.7-1.9-2.1-2.3
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
-------------
Profit From Continuing Operations
-5.3-3.9-5.2-3.4-2.5-2.6-10.9-1.3-1.7-1.6-1.8-2-2.2
Normalized EBITDA
-6.6-5.2-6.2-4.1-3.2-3.2-11.1-1.6-1.8-1.7-1.9-2.1-2.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Monopar Therapeutics Inc competitor comparison and performance snapshot within industry

Monopar Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Monopar Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Monopar Therapeutics Inc Annual Net Profit is $-14 Million which is growth of 12.0% YoY.

Monopar Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
-
-
 
Cost Of Rev. Ann.
-
-
 ----------
Gross Profit Ann.
-
-
 ----------
Operating Exp. Ann.
16.7%
20.8%
22.116.716.28.810.59.16.54.33.416.61.2
Operating Profit Ann.
-
-
-22.1-16.7-16.2-8.8-10.5-9.1-6.5-4.3-3.4-16.6-1.2
⌄
-
97.4%
4.230.40.4000.10.10.10.10
Other Exp. Ann.
-
-
 -0.2---0.1----
PBT Ann.
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.3-4.2-3.3-16.6-1.2
Tax Ann.
-
-
 --------0.1--
⌄
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.3-4.2-3.2-16.6-1.2
Diluted NI Avail to Com Stockholders Ann.
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.3-4.2-3.2-16.6-1.2
EPS Ann.
-
-
 -1.9-4.1-3.1-4.2-3.7-2.9-2.3-1.6-7.9-0.6
Diluted EPS Ann.
-
-
 -1.9-4.1-3.1-4.2-3.7-2.9-2.3-1.6-7.9-0.6
Number Of Shares End
48.4%
29.9%
 8.54.92.92.62.52.32.12.12.1-
Total Exp. Ann.
16.7%
20.8%
 16.716.28.810.59.16.54.33.416.61.2
Net Income Continuing Discontinued Operations Ann.
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.3-4.2-3.2-16.6-1.2
Normalized Income Ann.
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.4-4.2-3.2-16.6-1.2
Interest Income Ann.
-
97.4%
4.230.40.4000.10.10.10.10
Interest Ann.
-
-
 ----------
EBITDA Ann.
-
-
-22.1-16.7-16.2-8.8-10.5-9.1-6.5-4.3-3.4-16.6-1.2
Reconciled Cost Of Rev. Ann.
-
-
 ----------
Reconciled Depr. Ann.
-
-
 ----------
Profit From Continuing Operations Ann.
-
-
-17.8-13.7-15.6-8.4-10.5-9.1-6.3-4.2-3.2-16.6-1.2
Normalized EBITDA Ann.
-
-
-22.1-16.7-16.2-8.8-10.5-9.1-6.6-4.3-3.4-16.6-1.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
3.1%
2Y CAGR
37.8%
3Y CAGR
16.7%
5Y CAGR
20.8%
7Y CAGR
25.5%
Operating Expenses Annual Cr growth is lower than historical averages.

Monopar Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Monopar Therapeutics Inc Dec-2025 Total Shareholders Fund is $138 Million which is growth of 150.4% YoY.

  • POSITIVE

    Total Assets Monopar Therapeutics Inc Dec-2025 Total Assets is $141 Million which is growth of 133.4% YoY.

Monopar Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
120.1%
52.8%
140.760.37.413.220.516.913.47.39.92.9
⌄
-2.2%
19.3%
2.95.31.83.11.61.20.70.40.30.1
⌄
139%
54.4%
137.8555.610.118.915.712.66.99.62.8
Total Capitalization Ann.
139%
54.4%
137.8555.610.118.915.712.66.99.62.8
Tangible Assets Ann.
139%
54.4%
137.8555.610.118.915.712.66.99.62.8
Working Capital Ann.
139.7%
54.6%
137.7555.61018.915.612.56.98.82
Invested Capital Ann.
139%
54.4%
137.8555.610.118.915.712.66.99.62.8
Tangible Book Value Ann.
139%
54.4%
137.8555.610.118.915.712.66.99.62.8
Borrowings Ann.
-
-
0.2-0------
Net Debt Ann.
-
-
----------
Share Issued Ann.
37.1%
23.8%
6.76.132.62.52.32.12.12.12.1
Number Of Shares End
48.4%
29.9%
8.54.92.92.62.52.32.12.12.1-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
133.3%
2Y CAGR
336%
3Y CAGR
120.1%
5Y CAGR
52.8%
7Y CAGR
52.6%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-49.1%
2Y CAGR
22.5%
3Y CAGR
-4.5%
5Y CAGR
17.6%
7Y CAGR
31.4%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
150.5%
2Y CAGR
396.1%
3Y CAGR
139%
5Y CAGR
54.4%
7Y CAGR
53.4%
Total ShareHolders Funds Annual growth is higher than historical averages.

Monopar Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Monopar Therapeutics Inc Book Value Per Share is $19 which is growth of 130.4% YoY.

  • NEUTRAL

    ROE Monopar Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Monopar Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
RoA Ann. %
-
-
--46.09%-81.69%-62.32%-48.69%-41.72%-40.88%-37.43%-258.13%-40.95%
ROE Ann. %
-
-
--51.42%-107.19%-72.44%-52.57%-44.52%-43.23%-39.04%-265.93%-41.88%
ROIC %
-
-
--36.9-31.4-25.7-13.3-12.9-14.2-12.8-7.7-
OPM Ann. %
-
-
----------
Inventory Turnover Ratio Ann.
-
-
----------
Asset Turnover Ann. %
-
-
----------
Working Capital Turnover Ann.
-
-
Quick Ratio Ann.
-
-
-11.54.14.212.914.218.317.328.832.1
Current Ratio Ann.
-
-
-11.54.24.21314.318.318.329.332.5
Interest Coverage Ratio Ann.
-
-
----------
LT Debt To Equity Ann.
-
-
---------
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Monopar Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Monopar Therapeutics Inc Cash From Operating Activity is $-12 Million which is growth of -90.5% YoY.

  • NEGATIVE

    Net Cash Flow Monopar Therapeutics Inc Net Cash Flow is $16 Million which is growth of -58.7% YoY.

Monopar Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
-
-
-12.2-6.4-7.9-7.2-7.3-4.7-3-2.9-2.6-1.2
⌄
-
-
-63.5-14.34.9-4.9------
⌄
-
62%
91.659.32010.98.29.49.51.3
Cash Plus Cash Eqv. End Of Year Ann.
96.1%
29.9%
61.845.87.38.220.316.713.26.99.82.9
Net Increase In Cash Plus Cash Eqv.s Ann.
-
35.4%
15.938.6-0.9-12.13.63.56.3-2.96.90.1
Cash Plus Cash Eqv. Begin Of Year Ann.
31.2%
28.3%
45.87.38.220.316.713.26.99.82.92.8
Income Tax Paid Supplemental Data Ann.
-
-
----------
Interest Paid Supplemental Data Ann.
-
-
----------
Capex Ann.
-
-
----------
Issuance Of Capital Stock Ann.
983.2%
73%
127.159.42.10.110.98.210.24.71.3
Issuance Of Debt Ann.
-
-
----0.1----
Repayment Of Debt Ann.
-
-
----------
Repurchase Of Capital Stock Ann.
-
-
-35---------
Free Cash Flow Ann.
-
-
-12.2-6.4-7.9-7.2-7.3-4.7-3-2.9-2.6-1.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
54.5%
2Y CAGR
576.8%
5Y CAGR
62%
Cash from Financing Annual Activity growth is lower than historical averages.
×